针对CDK7的治疗有效地破坏了细胞周期进展和头癌的瘤信号传递
María Otero-Rosales1,2,3, Miguel Álvarez-González1,2,3, Irene Pazos4
1Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
头部和部状细胞癌 (HNSCC) 的向治疗方法有限. 这项研究确定了循环素依赖性激酶7 (CDK7) 作为一个有前途的治疗标,表明其抑制有效地抑制了临床前模型中的HNSCC生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 头角状细胞癌 (HNSCC) 是一种具有有限向治疗选择的侵袭性癌症.
- 识别新的治疗漏洞对于改善患者的治疗结果至关重要.
研究的目的:
- 通过全基因组CRISPR选,识别HNSCC中的可操作的遗传漏洞.
- 评估循环素依赖性激酶7 (CDK7) 作为HNSCC的潜在治疗标.
主要方法:
- 在五个HNSCC细胞系进行了全基因组CRISPR选.
- 进行了CDK7.7的遗传和药理抑制.
- 在患者衍生器官和异种移植小鼠模型中评估了抗瘤活性.
主要成果:
- CDK7被确定为所有测试的HNSCC细胞系中必不可少的和可向的基因.
- 在临床前模型中,CDK7抑制导致细胞循环停止,细胞亡,并抑制瘤生长,毒性最小.
- 抑制CDK7降低了细胞周期和DNA修复基因组的调节,减少了基本基因的转录.
结论:
- CDK7是HNSCC的一个有前途的治疗点.
- 选择性CDK7抑制在相关的临床前模型中显示出强大的抗瘤活性.
- 这些发现支持CDK7抑制剂用于HNSCC治疗的临床进展.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mitogens and the Cell Cycle
Positive Regulator Molecules
